Aquaporin-4 cerebrospinal fluid levels are higher in neurodegenerative dementia: looking at glymphatic system dysregulation.
Alzheimer’s disease
Amyloid-β
Aquaporin 4
Cerebrospinal fluid
Frontotemporal dementia
Glymphatic system
Journal
Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643
Informations de publication
Date de publication:
17 09 2022
17 09 2022
Historique:
received:
19
02
2022
accepted:
04
09
2022
entrez:
17
9
2022
pubmed:
18
9
2022
medline:
21
9
2022
Statut:
epublish
Résumé
Aquaporin-4 (AQP4) is a channel protein that plays a fundamental role in glymphatic system, a newly described pathway for fluid exchange in the central nervous system, as well as a central figure in a fascinating new theory for the pathophysiology of neurodegenerative diseases such as Alzheimer's disease (AD) and frontotemporal dementia (FTD). In this study, cerebrospinal fluid (CSF) concentration of AQP4, amyloid-β, total tau and P-tau were determined in 103 CSF samples from patients affected by neurodegenerative dementias (AD and FTD) or psychiatric diseases and 21 controls. Significantly higher levels of AQP4 were found in AD and FTD patients compared to subjects not affected by neurodegenerative diseases, and a significant, positive correlation between AQP4 and total tau levels was found. This evidence may pave the way for future studies focused on the role of this channel protein in the clinical assessment of the glymphatic function and degree of neurodegeneration.
Identifiants
pubmed: 36115967
doi: 10.1186/s13195-022-01077-6
pii: 10.1186/s13195-022-01077-6
pmc: PMC9482276
doi:
Substances chimiques
AQP4 protein, human
0
Aquaporin 4
0
tau Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
135Informations de copyright
© 2022. The Author(s).
Références
J Neurol Neurosurg Psychiatry. 2019 Nov;90(11):1221-1233
pubmed: 31542723
Prog Mol Biol Transl Sci. 2019;168:3-23
pubmed: 31699324
Arch Neurol. 1999 Mar;56(3):303-8
pubmed: 10190820
Am J Hum Biol. 2011 May-Jun;23(3):333-8
pubmed: 21484913
J Neurosci. 2014 Dec 3;34(49):16180-93
pubmed: 25471560
Nat Rev Neurosci. 2015 May;16(5):249-63
pubmed: 25891508
Mol Med. 2003 Mar-Apr;9(3-4):112-22
pubmed: 12865947
Metab Brain Dis. 2022 Apr;37(4):851-857
pubmed: 35286534
Cardiovasc Res. 2018 Sep 1;114(11):1462-1473
pubmed: 29726891
Neurol Clin. 2017 May;35(2):339-374
pubmed: 28410663
Nat Commun. 2018 Mar 15;9(1):1097
pubmed: 29545515
Alzheimers Dement. 2011 Jan;7(1):80-93
pubmed: 21255746
Ann Neurol. 2014 Dec;76(6):845-61
pubmed: 25204284
Neurobiol Dis. 2016 Sep;93:215-25
pubmed: 27234656
Alzheimers Dement. 2018 Apr;14(4):535-562
pubmed: 29653606
Ann Clin Transl Neurol. 2021 Jul;8(7):1456-1470
pubmed: 34129723
Brain. 2011 Sep;134(Pt 9):2456-77
pubmed: 21810890
Mol Neurodegener. 2015 Nov 02;10:58
pubmed: 26526066
Elife. 2017 Aug 21;6:
pubmed: 28826498
Mech Ageing Dev. 1999 May 3;108(2):165-72
pubmed: 10400309
JAMA Neurol. 2017 Jan 01;74(1):91-99
pubmed: 27893874
Brain. 2020 Aug 1;143(8):2576-2593
pubmed: 32705145
Sci Transl Med. 2012 Aug 15;4(147):147ra111
pubmed: 22896675
PLoS One. 2021 Oct 1;16(10):e0258165
pubmed: 34597351
Fluids Barriers CNS. 2022 Feb 3;19(1):9
pubmed: 35115036
J Alzheimers Dis. 2022;85(3):1009-1020
pubmed: 34897084
Alzheimers Dement. 2018 Nov;14(11):1505-1521
pubmed: 30316776
Handb Clin Neurol. 2019;167:139-148
pubmed: 31753130
Elife. 2018 Dec 18;7:
pubmed: 30561329
J Alzheimers Dis. 2019;69(3):663-669
pubmed: 31156164
Lancet Neurol. 2014 Jun;13(6):614-29
pubmed: 24849862
Nat Rev Neurol. 2015 Aug;11(8):457-70
pubmed: 26195256
Alzheimers Dement. 2020 Oct;16(10):1358-1371
pubmed: 32573951
Diagnosis (Berl). 2016 Mar 1;3(1):9-12
pubmed: 29540044
Brain. 2015 Jun;138(Pt 6):1454-76
pubmed: 25888551
Neurology. 2016 May 3;86(18):1736-43
pubmed: 27037234
J Clin Med. 2021 Mar 02;10(5):
pubmed: 33801197
Tumour Biol. 2013 Feb;34(1):387-93
pubmed: 23111756